[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Antithrombin Alfa.]
[G03XB02, ulipristal, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ulipristal.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Antithrombin Alfa.]
[A05AA03, cholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Cholic Acid.]
[L01EL01, ibrutinib, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Antithrombin Alfa.]
[G03AC08, etonogestrel, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Etonogestrel.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Antithrombin Alfa.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Antithrombin Alfa.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Antithrombin Alfa.]
[L01XH04, belinostat, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Belinostat.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Decitabine.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Antithrombin Alfa.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Antithrombin Alfa.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Antithrombin Alfa.]
[L01EF01, palbociclib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Palbociclib.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Tioclomarol.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Antithrombin Alfa.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Antithrombin Alfa.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Acemetacin.]
[L01CX01, trabectedin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Trabectedin.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Sugammadex.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Antithrombin Alfa.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Aloxiprin is combined with Antithrombin Alfa.]
[A05AA04, obeticholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Obeticholic acid.]
[L01AB01, busulfan, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Arsenic trioxide.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Antithrombin Alfa.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Antithrombin Alfa.]
[J01XX08, linezolid, The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Antithrombin Alfa.]
[J05AE09, tipranavir, The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin Alfa.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Antithrombin Alfa.]
[N04BD03, safinamide, The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Antithrombin Alfa.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Betrixaban.]
[L01BC06, capecitabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Vorinostat.]
[J01DC10, cefprozil, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefprozil.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Raltitrexed.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Antithrombin Alfa.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Antithrombin Alfa.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Antithrombin Alfa.]
[N03AF01, carbamazepine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carbamazepine.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Antithrombin Alfa.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-n1.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Antithrombin Alfa.]
[J01DE01, cefepime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefepime.]
[J01DD10, cefetamet, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefetamet.]
[J01DD09, cefodizime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefodizime.]
[J01DC11, ceforanide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceforanide.]
[J01DD13, cefpodoxime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefpodoxime.]
[J01DD14, ceftibuten, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftibuten.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Antithrombin Alfa.]
[L01AD01, carmustine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carmustine.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin Alfa.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Antithrombin Alfa.]
[J01DC04, cefaclor, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefaclor.]
[J01DB05, cefadroxil, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefadroxil.]
[J01DC03, cefamandole, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefamandole.]
[J01DB07, cefatrizine, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefatrizine.]
[J01DB04, cefazolin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefazolin.]
[J01DC09, cefmetazole, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefmetazole.]
[J01DC06, cefonicid, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefonicid.]
[J01DD12, cefoperazone, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefoperazone.]
[J01DD01, cefotaxime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefotetan.]
[J01DC07, cefotiam, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefotiam.]
[J01DC01, cefoxitin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefoxitin.]
[J01DD03, cefsulodin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefsulodin.]
[J01DD02, ceftazidime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftazidime.]
[J01DD07, ceftizoxime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftizoxime.]
[J01DD04, ceftriaxone, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftriaxone.]
[S01AA27, cefuroxime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefuroxime.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cyclothiazide.]
[J01DB01, cephalexin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cephalexin.]
[J01DB02, cephaloridine, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefaloridine.]
[J01DB03, cephalothin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefapirin.]
[J01DB09, cephradine, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefradine.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Antithrombin Alfa.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Antithrombin Alfa.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Antithrombin Alfa.]
[M01AH02, rofecoxib, The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Antithrombin Alfa.]
[L01XF03, bexarotene, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bexarotene.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Chloramphenicol.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Antithrombin Alfa.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Antithrombin Alfa.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Antithrombin Alfa.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Antithrombin Alfa.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Choline salicylate is combined with Antithrombin Alfa.]
[G03DC06, ethynodiol, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Antithrombin Alfa.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Antithrombin Alfa.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Fludarabine.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Antithrombin Alfa.]
[J01DD08, cefixime, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefixime.]
[J01DD15, cefdinir, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefdinir.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Peginterferon alfa-2b.]
[L01XA01, cisplatin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Antithrombin Alfa.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Antithrombin Alfa.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Antithrombin Alfa.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Antithrombin Alfa.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefpirome.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Antithrombin Alfa.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Nelarabine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Antithrombin Alfa.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Antithrombin Alfa.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Antithrombin Alfa.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Antithrombin Alfa.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Antithrombin Alfa.]
[L01EA01, imatinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Imatinib.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Antithrombin Alfa.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Antithrombin Alfa.]
[J01DC08, loracarbef, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Loracarbef.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Antithrombin Alfa.]
[N06AG02, moclobemide, The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Antithrombin Alfa.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Antithrombin Alfa.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Antithrombin Alfa.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Antithrombin Alfa.]
[L01AX04, dacarbazine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Antithrombin Alfa.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin Alfa.]
[N06AX06, nefazodone, The risk or severity of hemorrhage can be increased when Nefazodone is combined with Antithrombin Alfa.]
[G03DB04, nomegestrol, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Nomegestrol.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Antithrombin Alfa.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Antithrombin Alfa.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Antithrombin Alfa.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Antithrombin Alfa.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Antithrombin Alfa.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Antithrombin Alfa.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Antithrombin Alfa.]
[L01DC04, ixabepilone, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ixabepilone.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the anticoagulant activities of Antithrombin Alfa.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Antithrombin Alfa.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Antithrombin Alfa.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Lenalidomide.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Antithrombin Alfa.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Antithrombin Alfa.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Antithrombin Alfa.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Antithrombin Alfa.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Antithrombin Alfa.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Antithrombin Alfa.]
[S01XA23, sirolimus, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Sirolimus.]
[L01XG01, bortezomib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bortezomib.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Antithrombin Alfa.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Antithrombin Alfa.]
[L01DB01, doxorubicin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Doxorubicin.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Antithrombin Alfa.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Antithrombin Alfa.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Antithrombin Alfa.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Antithrombin Alfa.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Antithrombin Alfa.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Antithrombin Alfa.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Antithrombin Alfa.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Antithrombin Alfa.]
[N06AG03, toloxatone, The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Antithrombin Alfa.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Antithrombin Alfa.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Antithrombin Alfa.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Troxerutin.]
[L01CA04, vinorelbine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Vinorelbine.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Venlafaxine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Epirubicin.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Antithrombin Alfa.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Antithrombin Alfa.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Antithrombin Alfa.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Antithrombin Alfa.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Antithrombin Alfa.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Antithrombin Alfa.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the anticoagulant activities of Antithrombin Alfa.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Antithrombin Alfa.]
[M01AC06, meloxicam, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Antithrombin Alfa.]
[L01CB01, etoposide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Etoposide.]
[L04AD02, tacrolimus, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Tacrolimus.]
[N06AB08, fluvoxamine, The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Antithrombin Alfa.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin Alfa.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Antithrombin Alfa.]
[A05AA01, chenodeoxycholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Antithrombin Alfa.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Antithrombin Alfa.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin Alfa.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dexrazoxane.]
[A16AA01, levocarnitine, The therapeutic efficacy of Antithrombin Alfa can be increased when used in combination with Levocarnitine.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Antithrombin Alfa.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin Alfa.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Antithrombin Alfa.]
[L01BB06, clofarabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cladribine.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Antithrombin Alfa.]
[J02AX01, flucytosine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Flucytosine.]
[L01BC09, floxuridine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Antithrombin Alfa.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Antithrombin Alfa.]
[G01AX06, furazolidone, The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Antithrombin Alfa.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Antithrombin Alfa.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Antithrombin Alfa.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Antithrombin Alfa.]
[L01EX02, sorafenib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Sorafenib.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Fluindione.]
[L01CE02, irinotecan, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Irinotecan.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Antithrombin Alfa.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Antithrombin Alfa.]
[G03DC01, allylestrenol, Allylestrenol may decrease the anticoagulant activities of Antithrombin Alfa.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Antithrombin Alfa.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Altretamine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Antithrombin Alfa.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Hydroflumethiazide.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Antithrombin Alfa.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Hydroxyurea.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Antithrombin Alfa.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Antithrombin Alfa.]
[L01CD01, paclitaxel, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Paclitaxel.]
[L01CE01, topotecan, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Antithrombin Alfa.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hemorrhage can be increased when Milnacipran is combined with Antithrombin Alfa.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Antithrombin Alfa is combined with Collagenase clostridium histolyticum.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Antithrombin Alfa.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfacon-1.]
[N06AF05, iproniazid, The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Antithrombin Alfa.]
[N06AF01, isocarboxazid, The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Antithrombin Alfa.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Antithrombin Alfa.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Antithrombin Alfa.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Antithrombin Alfa.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Antithrombin Alfa.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Antithrombin Alfa.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Antithrombin Alfa is combined with Deferasirox.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Antithrombin Alfa.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Antithrombin Alfa.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Lomustine.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Antithrombin Alfa.]
[L01EG01, temsirolimus, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Temsirolimus.]
[L01EA03, nilotinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Antithrombin Alfa.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Antithrombin Alfa.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Antithrombin Alfa.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Antithrombin Alfa.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Antithrombin Alfa.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Melphalan.]
[H03BB02, methimazole, Methimazole may increase the anticoagulant activities of Antithrombin Alfa.]
[L01BA04, pemetrexed, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Pemetrexed.]
[L04AX03, methotrexate, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Methotrexate.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Antithrombin Alfa.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Antithrombin Alfa.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Antithrombin Alfa.]
[G03XB01, mifepristone, The risk or severity of adverse effects can be increased when Mifepristone is combined with Antithrombin Alfa.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Antithrombin Alfa.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Aldesleukin.]
[J01DD06, moxalactam, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Latamoxef.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon beta-1b.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Antithrombin Alfa.]
[N06AX21, duloxetine, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Antithrombin Alfa.]
[L01CD02, docetaxel, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Docetaxel.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Antithrombin Alfa.]
[N06AX23, desvenlafaxine, The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Antithrombin Alfa.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Amsacrine.]
[N06AF02, nialamide, The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Antithrombin Alfa.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Antithrombin Alfa.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Antithrombin Alfa.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Antithrombin Alfa.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin Alfa.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Antithrombin Alfa.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Antithrombin Alfa.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Antithrombin Alfa.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Antithrombin Alfa.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin Alfa.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Antithrombin Alfa.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Antithrombin Alfa.]
[C02KC01, pargyline, The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Antithrombin Alfa.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Penicillamine.]
[L01XX08, pentostatin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Pentostatin.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Antithrombin Alfa can be increased when used in combination with Pentoxifylline.]
[N06AF03, phenelzine, The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Antithrombin Alfa.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Antithrombin Alfa.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Antithrombin Alfa.]
[M02AA01, phenylbutazone, The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Antithrombin Alfa.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Antithrombin Alfa.]
[J01DD16, cefditoren, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefditoren.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Antithrombin Alfa.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Antithrombin Alfa.]
[C03AA05, polythiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Polythiazide.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Antithrombin Alfa.]
[S01HA05, procaine, The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Antithrombin Alfa.]
[L01XB01, procarbazine, The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin Alfa.]
[G03DA04, progesterone, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Progesterone.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Antithrombin Alfa.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Antithrombin Alfa.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Antithrombin Alfa.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Antithrombin Alfa is combined with Collagenase clostridium histolyticum.]
[C01BA01, quinidine, The therapeutic efficacy of Antithrombin Alfa can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Antithrombin Alfa can be increased when used in combination with Quinine.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Antithrombin Alfa.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Antithrombin Alfa.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Antithrombin Alfa.]
[N04BD01, selegiline, The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Antithrombin Alfa.]
[L01FA03, obinutuzumab, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Obinutuzumab.]
[L01CD04, cabazitaxel, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cabazitaxel.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Antithrombin Alfa.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Streptozocin.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Antithrombin Alfa.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Antithrombin Alfa.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Antithrombin Alfa.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Antithrombin Alfa.]
[L01CB02, teniposide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Teniposide.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may increase the anticoagulant activities of Antithrombin Alfa.]
[G03BA03, testosterone, Testosterone may increase the anticoagulant activities of Antithrombin Alfa.]
[J01DI02, ceftaroline fosamil, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Ceftaroline fosamil.]
[L04AX02, thalidomide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Tioguanine.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Antithrombin Alfa.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Antithrombin Alfa.]
[N06AF04, tranylcypromine, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Antithrombin Alfa.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Antithrombin Alfa.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Antithrombin Alfa.]
[S01BA05, triamcinolone, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Triamcinolone.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Trichlormethiazide.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Antithrombin Alfa.]
[B01AF01, rivaroxaban, Antithrombin Alfa may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Antithrombin Alfa.]
[L01CA01, vinblastine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Vinblastine.]
[L01CA03, vindesine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Vindesine.]
[A11HA03, vitamin E, Vitamin E may increase the anticoagulant activities of Antithrombin Alfa.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Antithrombin Alfa.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Zidovudine.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Antithrombin Alfa.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the anticoagulant activities of Antithrombin Alfa.]
[L01EJ01, ruxolitinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Rituximab.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Azacitidine.]
[L01BC05, gemcitabine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemcitabine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bosutinib.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Antithrombin Alfa.]
[L01AA09, bendamustine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bendamustine.]
[N04BD02, rasagiline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Antithrombin Alfa.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Tofacitinib.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Antithrombin Alfa is combined with Sildenafil.]
[L01EA05, ponatinib, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ponatinib.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Antithrombin Alfa.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Antithrombin Alfa.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Antithrombin Alfa.]
[L04AA18, everolimus, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Everolimus.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Antithrombin Alfa.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Trastuzumab emtansine.]
[A05AA02, ursodiol, The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Ursodeoxycholic acid.]
[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Antithrombin III human.]
[G03XB02, ulipristal, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Ulipristal.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Antithrombin III human.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Antithrombin III human.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M09AX08, golodirsen, Antithrombin III human may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Dexpanthenol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Antithrombin III human may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Antithrombin III human.]
[M01AH02, rofecoxib, The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Antithrombin III human.]
[L01XF03, bexarotene, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bexarotene.]
[C08CA16, clevidipine, Clevidipine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Chloramphenicol.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Antithrombin III human.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin III human.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Antithrombin III human.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Antithrombin III human.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Antithrombin III human.]
[G03DC06, ethynodiol, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Antithrombin III human.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Antithrombin III human.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Chondroitin sulfate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Antithrombin III human.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD08, cefixime, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Cefixime.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XA01, cisplatin, Antithrombin III human may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Antithrombin III human.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Antithrombin III human.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ropeginterferon alfa-2b.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Antithrombin III human.]
[N01BB10, levobupivacaine, Levobupivacaine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AA04, clomipramine, Clomipramine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH02, clozapine, Clozapine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01GB12, arbekacin, Antithrombin III human may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Antithrombin III human.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01XB01, colistin, Antithrombin III human may decrease the excretion rate of Colistin which could result in a higher serum level.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A04AA03, tropisetron, Antithrombin III human may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Antithrombin III human.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Nelarabine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Antithrombin III human.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C05BB03, invert sugar, Invert sugar may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08AB05, iopromide, Iopromide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08AB07, ioversol, Ioversol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08AB12, ioxilan, Ioxilan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Antithrombin III human.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Antithrombin III human.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Antithrombin III human.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BA10, ketazolam, Ketazolam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Antithrombin III human.]
[L01EA01, imatinib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Imatinib.]
[N03AX09, lamotrigine, Lamotrigine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N07BC04, lofexidine, Lofexidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Antithrombin III human.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Antithrombin III human.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Magnesium carbonate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Melperone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Antithrombin III human.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AG02, moclobemide, The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Antithrombin III human.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Antithrombin III human.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Antithrombin III human.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Antithrombin III human.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Daunorubicin.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Antithrombin III human.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Antithrombin III human.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of hemorrhage can be increased when Nefazodone is combined with Antithrombin III human.]
[C01DX16, nicorandil, Nicorandil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DB04, nomegestrol, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Nomegestrol.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Antithrombin III human.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Antithrombin III human.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Antithrombin III human.]
[N06AA01, desipramine, Desipramine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CH02, indigo carmine, Indigotindisulfonic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Antithrombin III human.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Antithrombin III human.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Antithrombin III human.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R05DA08, pholcodine, Pholcodine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Antithrombin III human.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01DC04, ixabepilone, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ixabepilone.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the anticoagulant activities of Antithrombin III human.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[D07XC04, diflucortolone, Difluocortolone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Antithrombin III human.]
[C01AA05, digoxin, Antithrombin III human may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Antithrombin III human.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Antithrombin III human.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Antithrombin III human.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Antithrombin III human.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Antithrombin III human.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Antithrombin III human.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Antithrombin III human.]
[S01XA23, sirolimus, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Sirolimus.]
[S01AX06, resorcinol, Resorcinol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R06AE09, levocetirizine, Levocetirizine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bortezomib.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Antithrombin III human.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Antithrombin III human.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AA12, doxepin, Doxepin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01DB01, doxorubicin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Doxorubicin.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Antithrombin III human.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Antithrombin III human.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Antithrombin III human.]
[A12CA02, sodium sulfate, Sodium sulfate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Antithrombin III human.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Antithrombin III human.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Antithrombin III human.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Antithrombin III human.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Antithrombin III human.]
[N06AG03, toloxatone, The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Antithrombin III human.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Antithrombin III human.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Chloral hydrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Antithrombin III human.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Troxerutin.]
[L01CA04, vinorelbine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Vinorelbine.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Venlafaxine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Epirubicin.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Antithrombin III human.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Antithrombin III human.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Antithrombin III human.]
[L03AX05, pidotimod, Pidotimod may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Antithrombin III human.]
[N05CD04, estazolam, Estazolam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Antithrombin III human.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Antithrombin III human.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the anticoagulant activities of Antithrombin III human.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Antithrombin III human.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AC06, meloxicam, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Antithrombin III human.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Etoposide.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Antithrombin III human.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Sodium aurothiomalate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin III human.]
[A05AA01, chenodeoxycholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Antithrombin III human.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Antithrombin III human.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A16AA01, levocarnitine, The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Levocarnitine.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Antithrombin III human.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin III human.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Antithrombin III human.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cladribine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Antithrombin III human.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Antithrombin III human.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Antithrombin III human.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC03, tegafur, Tegafur may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G01AX06, furazolidone, The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Antithrombin III human.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Antithrombin III human.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Antithrombin III human.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Antithrombin III human.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01CB04, aurothioglucose, Aurothioglucose may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05AD01, haloperidol, Haloperidol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05AH04, quetiapine, Quetiapine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06BX13, idebenone, Idebenone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Irinotecan.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Antithrombin III human.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Antithrombin III human.]
[G03DC01, allylestrenol, Allylestrenol may decrease the anticoagulant activities of Antithrombin III human.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Antithrombin III human.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Altretamine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Antithrombin III human.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Antithrombin III human may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BD06, propiverine, Antithrombin III human may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Hydroxyethyl Starch may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Antithrombin III human.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Hydroxyurea.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B05XA08, sodium acetate, Sodium acetate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Antithrombin III human.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Antithrombin III human.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CD01, paclitaxel, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Paclitaxel.]
[R01AD07, tixocortol, Tixocortol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Antithrombin III human.]
[A11HA07, inositol, Antithrombin III human may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hemorrhage can be increased when Milnacipran is combined with Antithrombin III human.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Collagenase clostridium histolyticum.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Antithrombin III human.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfacon-1.]
[V03AB01, ipecac, Antithrombin III human may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AF05, iproniazid, The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Antithrombin III human.]
[N06AF01, isocarboxazid, The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Antithrombin III human.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AX05, inosine pranobex, Antithrombin III human may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Antithrombin III human.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Antithrombin III human.]
[S01AA24, kanamycin, Antithrombin III human may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Ketamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Antithrombin III human.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Antithrombin III human.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Antithrombin III human.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Antithrombin III human is combined with Deferasirox.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Antithrombin III human.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Antithrombin III human.]
[S01AA21, amikacin, Antithrombin III human may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Lomustine.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Antithrombin III human.]
[L01EG01, temsirolimus, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Magnesium chloride may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Antithrombin III human.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Antithrombin III human.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Antithrombin III human.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Antithrombin III human.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Antithrombin III human.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Melphalan.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Paliperidone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06BA03, methamphetamine, Metamfetamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Methimazole may increase the anticoagulant activities of Antithrombin III human.]
[L01BA04, pemetrexed, Antithrombin III human may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Antithrombin III human.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A03FA01, metoclopramide, Metoclopramide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Antithrombin III human.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Antithrombin III human.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of adverse effects can be increased when Mifepristone is combined with Antithrombin III human.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Antithrombin III human.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Mitoxantrone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Certolizumab pegol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon beta-1b.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Antithrombin III human.]
[N06AX21, duloxetine, The risk or severity of hemorrhage can be increased when Duloxetine is combined with Antithrombin III human.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Docetaxel.]
[S03AA01, neomycin, Antithrombin III human may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Antithrombin III human.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA23, netilmicin, Antithrombin III human may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Antithrombin III human.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Amsacrine.]
[N06AF02, nialamide, The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Antithrombin III human.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Antithrombin III human.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Antithrombin III human.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Antithrombin III human.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin III human.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Antithrombin III human.]
[N02AA02, opium, Opium may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Antithrombin III human.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Antithrombin III human.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Antithrombin III human.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin III human.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Antithrombin III human.]
[J04AB30, capreomycin, Antithrombin III human may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Antithrombin III human.]
[C02KC01, pargyline, The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Antithrombin III human.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BD11, fesoterodine, Fesoterodine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C07AA23, penbutolol, Penbutolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XX08, pentostatin, Antithrombin III human may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Pentoxifylline.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Antithrombin III human.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Antithrombin III human.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Antithrombin III human.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Antithrombin III human.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06BX03, piracetam, Piracetam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Antithrombin III human.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Antithrombin III human.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Antithrombin III human.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Antithrombin III human.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01BA02, procainamide, Antithrombin III human may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Antithrombin III human.]
[L01XB01, procarbazine, The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin III human.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03DA04, progesterone, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Progesterone.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Antithrombin III human.]
[R06AD02, promethazine, Promethazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Antithrombin III human.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Antithrombin III human.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[P02CC01, pyrantel, Pyrantel may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Collagenase clostridium histolyticum.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C01BA01, quinidine, The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Antithrombin III human can be increased when used in combination with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Antithrombin III human.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Antithrombin III human.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Antithrombin III human.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N04BD01, selegiline, The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Antithrombin III human.]
[L01FA03, obinutuzumab, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Obinutuzumab.]
[J01GB08, sisomicin, Antithrombin III human may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sodium fluoride may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CD04, cabazitaxel, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Antithrombin III human.]
[J01GA01, streptomycin, Antithrombin III human may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Streptozocin.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01CG01, sulbactam, Sulbactam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Antithrombin III human.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Antithrombin III human.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Antithrombin III human.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Antithrombin III human.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.]
[G03BA03, testosterone, Testosterone may increase the anticoagulant activities of Antithrombin III human.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AX02, thalidomide, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Tioguanine.]
[G04BE06, moxisylyte, Moxisylyte may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05AL03, tiapride, Antithrombin III human may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Antithrombin III human.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA12, tobramycin, Antithrombin III human may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Antithrombin III human.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AF04, tranylcypromine, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Antithrombin III human.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Antithrombin III human.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Antithrombin III human.]
[S01BA05, triamcinolone, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A03AA05, trimebutine, Trimebutine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R02AA14, oxyquinoline, Oxyquinoline may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Antithrombin III human.]
[S01AA28, vancomycin, Antithrombin III human may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AF01, rivaroxaban, Antithrombin III human may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Antithrombin III human.]
[C08DA01, verapamil, Verapamil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AX09, viloxazine, Viloxazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Vinblastine.]
[L01CA03, vindesine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Vindesine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A11HA03, vitamin E, Vitamin E may increase the anticoagulant activities of Antithrombin III human.]
[B01AA03, warfarin, Antithrombin III human may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Zidovudine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin III human.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Antithrombin III human.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the anticoagulant activities of Antithrombin III human.]
[L01EJ01, ruxolitinib, Ruxolitinib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Rituximab.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Lorcaserin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BD12, mirabegron, Mirabegron may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Carfilzomib.]
[L02BB04, enzalutamide, Enzalutamide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EA04, bosutinib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bosutinib.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Antithrombin III human.]
[D02BA02, octinoxate, Octinoxate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bendamustine.]
[N04BD02, rasagiline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Antithrombin III human.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Tofacitinib.]
[V09IX04, fluorodeoxyglucose F18, Fludeoxyglucose (18F) may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Antithrombin III human is combined with Sildenafil.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ponatinib.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Antithrombin III human.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Glycerol phenylbutyrate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Pomalidomide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Antithrombin III human.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AA12, ancestim, Ancestim may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Antithrombin III human.]
[L04AA18, everolimus, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Antithrombin III human.]
[L01EE01, trametinib, Trametinib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Florbetapir (18F) may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Antithrombin III human.]
[A10BJ03, lixisenatide, Lixisenatide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A05AA03, cholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Cholic Acid.]
[C02KX04, macitentan, Macitentan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Antithrombin III human.]
[N06AX26, vortioxetine, Vortioxetine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[G03AC08, etonogestrel, The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Etonogestrel.]
[J05AP08, sofosbuvir, Sofosbuvir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05CH03, tasimelteon, Tasimelteon may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L04AA32, apremilast, Apremilast may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02BG02, formestane, Formestane may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Antithrombin III human.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Antithrombin III human.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Antithrombin III human.]
[L01XH04, belinostat, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Belinostat.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Decitabine.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Antithrombin III human.]
[S03AA06, gentamicin, Antithrombin III human may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Antithrombin III human.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Antithrombin III human.]
[L01EF01, palbociclib, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Palbociclib.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Antithrombin III human.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Antithrombin III human.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Idarucizumab may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Antithrombin III human.]
[L01XG03, ixazomib, Ixazomib may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Sugammadex.]
[M04AB05, lesinurad, Lesinurad may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Antithrombin III human.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Aloxiprin is combined with Antithrombin III human.]
[N03AX23, brivaracetam, Brivaracetam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BA08, bromazepam, Bromazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Antithrombin III human may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A05AA04, obeticholic acid, The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Levobupivacaine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Busulfan.]
[L01XX27, arsenic trioxide, Arsenic trioxide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Antithrombin III human.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Antithrombin III human.]
[A06AH05, naldemedine, Antithrombin III human may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Antithrombin III human may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[P01CA02, benznidazole, Antithrombin III human may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Antithrombin III human.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J05AE09, tipranavir, The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin III human.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Antithrombin III human.]
[N07XX13, valbenazine, Antithrombin III human may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Antithrombin III human.]
[J01MA23, delafloxacin, Antithrombin III human may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Betrixaban.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Vorinostat.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Raltitrexed.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Antithrombin III human.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Antithrombin III human.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Antithrombin III human.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Acrivastine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L02BB05, apalutamide, Antithrombin III human may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Antithrombin III human may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Antithrombin III human.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-n1.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Antithrombin III human.]
[L04AA37, baricitinib, Antithrombin III human may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01GB14, plazomicin, Antithrombin III human may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N03AX17, stiripentol, Stiripentol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[D08AE05, chloroxylenol, Chloroxylenol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Antithrombin III human.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin III human.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Antithrombin III human.]
[N06BA14, solriamfetol, Antithrombin III human may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[N07XX11, pitolisant, Antithrombin III human may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of bleeding can be increased when Antithrombin III human is combined with Trastuzumab emtansine.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Choline salicylate is combined with Antithrombin III human.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Technetium Tc-99m exametazime may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Florbetaben (18F) may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Antithrombin III human.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Antithrombin III human.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.]
[A05AA02, ursodiol, The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Ursodeoxycholic acid.]
